Dapre yon rapò ki soti nan Grand View Research "Bezwen medikal segondè ki pa satisfè ak inisyativ gouvènman an pou diminye maladi sikyatrik ak newolojik yo ap kondwi mache a pou sistèm nève santral (CNS) terapetik.
Dapre KI MOUN KI, ekonomi mondyal la pèdi akòz depresyon ak enkyetid se plis pase USD $ 1 billions pa ane ak k ap monte baz pasyan nan sante mantal globalman espere ogmante ekonomi an pèdi pa USD $ 16 billions nan 2030. Mache a kenbe gwo opòtinite kwasans nan lavni. ak gwo jwè yo ap adopte diferan estrateji maketing tankou devlopman nouvo pwodwi, kolaborasyon, ekspansyon jeyografik, fizyon ak akizisyon, ak apwobasyon nouvo pwodwi, pou ranfòse pozisyon yo." Rapò a prevwa ke gwosè mache terapetik mondyal sistèm nève santral la espere rive nan 205.0 milya dola pa 2028 e li espere pou elaji nan yon CAGR de 7.4% jiska 2028.
Rapò a te kontinye: "Prezans pwodwi tiyo fò pa gwo konpayi pharmaceutique... ak lòt moun espere akselere kwasans mache sou peryòd prévision a. Anplis de sa, lòt konpayi pharmaceutique yo tou patisipe aktivman nan devlopman nan terapi roman ak envesti lou yo devlope terapetik efikas pou tretman CNS ki asosye maladi. Aktif Biotechs nan mache yo jodi a genyen: Pasithea Therapeutics Corp., Alkermes plc, Passage Bio, Inc., Acadia Healthcare Company, Inc., atai Life Sciences.
Pifò nan dwòg devlopman an reta yo se pou tretman maladi nerodejeneratif tankou maladi alzayme a, paralezi miltip, maladi Parkinson, ak paralezit lateral amyotwofik... kèk nan dwòg potansyèl ki ta ka komèrsyalize nan pwochen senk a uit ane pou tretman an. divès kalite endikasyon nan maladi neurodegenerative. Apa de maladi neurodegenerative, migrèn, eskizofreni, ak epilepsi se pi gwo endikasyon maladi CNS ki gen kandida potansyèl dwòg nan tiyo. Konpayi famasetik yo ap adopte estrateji tankou devlopman pwodwi, fizyon ak akizisyon, ak kolaborasyon pou ranfòse pozisyon yo nan mache."
KISA POU RETIRE NAN ATIK SA A:
- Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis… some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders.
- According to WHO, the global economy loses due to depression and anxiety is more than USD $1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD $16 trillion in 2030.
- Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.
